Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401455 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL30477937 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL29398070 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL30252212 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL119402 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL2366563 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL1738651 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL31575313 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL2367241 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL12055781 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-4074328-A1 | INTERMEDIATES OF CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | Seagen Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-07-21 | — | — | US | disclosed |
| EP-3383420-B1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| WO-2014141104-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-2007794-A1 | LYSOBACTIN AMIDES | AiCuris GmbH & Co. KG (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118691-A1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275083-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | CASP3 3005/4885MDM4 1288/4885TP53 13/4885 |
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | CASP3 332/4885MDM4 3630/4885TP53 2587/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | CASP3 198/4885MDM4 3170/4885TP53 2720/4885 |
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | CASP3 619/4885MDM4 3785/4885TP53 383/4885 |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | CASP3 1499/4885MDM4 4684/4885TP53 1916/4885 |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | CASP3 1499/4885MDM4 4684/4885TP53 1916/4885 |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | CASP3 1499/4885MDM4 4684/4885TP53 1916/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | CASP3 1499/4885MDM4 4684/4885TP53 1916/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | CASP3 2783/4885MDM4 1648/4885TP53 614/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | CASP3 1499/4885MDM4 4684/4885TP53 1916/4885 |
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | CASP3 2701/4885MDM4 4264/4885TP53 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.